The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Peripheral Arterial Disease (PAD) Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.
The global Peripheral Arterial Disease (PAD) Therapeutics market size is expected to reach US$ 4249.9 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Peripheral Arterial Disease (PAD) Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Peripheral Arterial Disease (PAD) Therapeutics market. Anti-Platelet Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dual Antiplatelet Therapy Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peripheral Arterial Disease (PAD) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peripheral Arterial Disease (PAD) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peripheral Arterial Disease (PAD) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peripheral Arterial Disease (PAD) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peripheral Arterial Disease (PAD) Therapeutics covered in this report include AstraZeneca Plc. (UK), Bayer HealthCare Pharmaceuticals (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), Proteon Therapeutics, Inc. (US), Sanofi S.A. (France), Symic Bio, Inc. (US), TheraVasc Inc. (US) and AnGes MG, Inc. (Japan), etc.
The global Peripheral Arterial Disease (PAD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Global Peripheral Arterial Disease (PAD) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peripheral Arterial Disease (PAD) Therapeutics market, Segment by Type:
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Global Peripheral Arterial Disease (PAD) Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peripheral Arterial Disease (PAD) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.
The global Peripheral Arterial Disease (PAD) Therapeutics market size is expected to reach US$ 4249.9 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Peripheral Arterial Disease (PAD) Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Peripheral Arterial Disease (PAD) Therapeutics market. Anti-Platelet Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dual Antiplatelet Therapy Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peripheral Arterial Disease (PAD) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peripheral Arterial Disease (PAD) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peripheral Arterial Disease (PAD) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peripheral Arterial Disease (PAD) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peripheral Arterial Disease (PAD) Therapeutics covered in this report include AstraZeneca Plc. (UK), Bayer HealthCare Pharmaceuticals (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), Proteon Therapeutics, Inc. (US), Sanofi S.A. (France), Symic Bio, Inc. (US), TheraVasc Inc. (US) and AnGes MG, Inc. (Japan), etc.
The global Peripheral Arterial Disease (PAD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Global Peripheral Arterial Disease (PAD) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peripheral Arterial Disease (PAD) Therapeutics market, Segment by Type:
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Global Peripheral Arterial Disease (PAD) Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peripheral Arterial Disease (PAD) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Peripheral Arterial Disease (PAD) Therapeutics
1.1 Peripheral Arterial Disease (PAD) Therapeutics Market Overview
1.1.1 Peripheral Arterial Disease (PAD) Therapeutics Product Scope
1.1.2 Peripheral Arterial Disease (PAD) Therapeutics Market Status and Outlook
1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2018-2029)
1.4 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
1.6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
1.6.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2029)
2 Peripheral Arterial Disease (PAD) Therapeutics Market by Type
2.1 Introduction
2.1.1 Anti-Platelet Drugs
2.1.2 Dual Antiplatelet Therapy Drugs
2.1.3 Others
2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Peripheral Arterial Disease (PAD) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Peripheral Arterial Disease (PAD) Therapeutics Competition Analysis by Players
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
4.4 Global Top Players Peripheral Arterial Disease (PAD) Therapeutics Headquarters and Area Served
4.5 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca Plc. (UK)
5.1.1 AstraZeneca Plc. (UK) Profile
5.1.2 AstraZeneca Plc. (UK) Main Business
5.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.1.4 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Plc. (UK) Recent Developments
5.2 Bayer HealthCare Pharmaceuticals (Germany)
5.2.1 Bayer HealthCare Pharmaceuticals (Germany) Profile
5.2.2 Bayer HealthCare Pharmaceuticals (Germany) Main Business
5.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.2.4 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Developments
5.3 Bristol-Myers Squibb Company (US)
5.3.1 Bristol-Myers Squibb Company (US) Profile
5.3.2 Bristol-Myers Squibb Company (US) Main Business
5.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.3.4 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Merck & Co., Inc. (US) Recent Developments
5.4 Merck & Co., Inc. (US)
5.4.1 Merck & Co., Inc. (US) Profile
5.4.2 Merck & Co., Inc. (US) Main Business
5.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.4.4 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Merck & Co., Inc. (US) Recent Developments
5.5 Proteon Therapeutics, Inc. (US)
5.5.1 Proteon Therapeutics, Inc. (US) Profile
5.5.2 Proteon Therapeutics, Inc. (US) Main Business
5.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.5.4 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Proteon Therapeutics, Inc. (US) Recent Developments
5.6 Sanofi S.A. (France)
5.6.1 Sanofi S.A. (France) Profile
5.6.2 Sanofi S.A. (France) Main Business
5.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.6.4 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Sanofi S.A. (France) Recent Developments
5.7 Symic Bio, Inc. (US)
5.7.1 Symic Bio, Inc. (US) Profile
5.7.2 Symic Bio, Inc. (US) Main Business
5.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.7.4 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Symic Bio, Inc. (US) Recent Developments
5.8 TheraVasc Inc. (US)
5.8.1 TheraVasc Inc. (US) Profile
5.8.2 TheraVasc Inc. (US) Main Business
5.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.8.4 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 TheraVasc Inc. (US) Recent Developments
5.9 AnGes MG, Inc. (Japan)
5.9.1 AnGes MG, Inc. (Japan) Profile
5.9.2 AnGes MG, Inc. (Japan) Main Business
5.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.9.4 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 AnGes MG, Inc. (Japan) Recent Developments
5.10 Athersys, Inc. (US)
5.10.1 Athersys, Inc. (US) Profile
5.10.2 Athersys, Inc. (US) Main Business
5.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.10.4 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Athersys, Inc. (US) Recent Developments
5.11 Betagenon AB (Sweden)
5.11.1 Betagenon AB (Sweden) Profile
5.11.2 Betagenon AB (Sweden) Main Business
5.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.11.4 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Betagenon AB (Sweden) Recent Developments
5.12 miRagen Therapeutics, Inc. (US)
5.12.1 miRagen Therapeutics, Inc. (US) Profile
5.12.2 miRagen Therapeutics, Inc. (US) Main Business
5.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.12.4 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 miRagen Therapeutics, Inc. (US) Recent Developments
5.13 Multi Gene Vascular Systems Ltd (Israel)
5.13.1 Multi Gene Vascular Systems Ltd (Israel) Profile
5.13.2 Multi Gene Vascular Systems Ltd (Israel) Main Business
5.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.13.4 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Developments
5.14 ViroMed Co. Ltd. (Korea)
5.14.1 ViroMed Co. Ltd. (Korea) Profile
5.14.2 ViroMed Co. Ltd. (Korea) Main Business
5.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Products, Services and Solutions
5.14.4 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 ViroMed Co. Ltd. (Korea) Recent Developments
6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Peripheral Arterial Disease (PAD) Therapeutics Market Dynamics
11.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Trends
11.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
11.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
11.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
